Elacestrant Shows Survival Benefit in Certain ER+/HER2- Advanced Breast CancerJune 4th 2023
A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.
Following Prior Immunotherapy Resistance in Advanced PD-L1+ NSCLC Rilvegostomig Shows PromiseJune 4th 2023
Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.
Lower Dose of Trastuzumab Deruxtecan Shows Antitumor Activity in HER2+ mCRCJune 4th 2023
Results from the DESTINY-CRC02 study showed that the lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.
Dostalimab Plus Chemotherapy Shows Similar HRQOL Results in Patients with Endometrial CancerJune 4th 2023
New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.
BRCA-Mutated mCRPC Has Worse Outcomes Than Non-BRCA HRR PopulationJune 4th 2023
When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.
Adjuvant Osimertinib Extends Survival in EGFR-Positive, Stage IB-IIIA NSCLC
ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.
STRIDE Regimen Exhibits Manageable Safety in Patients With uHCCJune 3rd 2023
According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.